< Back to previous page
Researcher
Bart Vandekerckhove
- Keywords:Advanced therapy medicinal products, GMP, immunotherapy
- Disciplines:Other medical and health sciences not elsewhere classified, Adaptive immunology, Medicinal products not elsewhere classified, Cancer therapy
Affiliations
- Department of Diagnostic Sciences (Department)
Member
From1 Oct 2018 → Today - Department of Clinical chemistry, microbiology and immunology (Department)
Member
From1 Jan 1993 → 30 Sep 2018
Projects
1 - 10 of 30
- Chromatography for the purification of in vitro transcribed RNA as part of the production process of lipid nanoparticle vaccines and cancer immunotherapeutics for use in clinical trials (C-puRNA)From20 Dec 2023 → TodayFunding: IOF - technology validation in lab
- Chimeric antigen receptor unconventional T cell therapy (CAR-uT) for the treatment of solid tumorsFrom1 Nov 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Optimisation of CD70-targeted adoptive cell therapyFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- ABSL3 mice housing system to develop new therapies against virulent pathogensFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Optimising CD70-specific T cell therapy for solitary and haematological malignanciesFrom1 Nov 2022 → 31 Oct 2023Funding: BOF - doctoral mandates
- Chimeric antigen receptor unconventional T cell therapy (CAR-uT) for the treatment of solid tumorsFrom1 Nov 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Patient-friendly tumor sampling for the design, and reduction of the production time of a neoepitope dendritic cell vaccine for patients presenting with inoperable non small cell lung carcinoma (NEO4LUNG)From1 Oct 2022 → TodayFunding: Nonprofit institution or equivalents
- CARTAGENA- Development of an innovative platform and complementary assays for screening and selection of CAR-T cellsFrom15 Jul 2022 → TodayFunding: IOF - technology validation in lab
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- White light laser-based confocal fluorescence lifetime imaging microscope for multi-parameter 3D live imagingFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
Publications
31 - 34 of 34
- CD4 and CD8 TCR alpha beta cells are selected on MHC expressed on thymocyte precursors in OP9-DL1 cultures(2009)Volume: 114
Authors: Stefanie Van Coppernolle, Bart Vandekerckhove, Greet Verstichel, Imke Velghe, Tom Taghon, Georges Leclercq, Jean Plum, Tessa Kerre
Pages: 1414 - 1414 - Generation of T cells from human embryonic stem cells(2008)Volume: 112
Authors: Frank Timmermans, Imke Velghe, Lieve Vanwalleghem, Magda De Smedt, Stefanie Van Coppernolle, Georges Leclercq, Tom Taghon, Harry Moore, Anton W Langerak, Tessa Kerre, et al.
Pages: 543 - 543 - OP9-DL1 Cell Line Supports the Development of Phenotypically and Functionally Mature Tcr alpha beta And Tcr gamma delta T Cells, through Both Conventional and Aberrant Developmental Pathways(2008)Volume: 112
Authors: Tessa Kerre, Greet Verstichel, Stefanie Van Coppernolle, Imke Velghe, Frank Timmermans, Jean Plum, Bart Vandekerckhove
Pages: 998 - 998 - GUIDELINES FOR THE USE OF FRESH FROZEN PLASMA(2008)
Authors: D. De Backer, Bart Vandekerckhove, S. Stanworth, L. Williamson, C. Hermans, P. Van der Linden, R. Hubner, P. Baele, K. Jochmans, A. Ferrant, et al.
Pages: 381 - 390